Spiders may have evolved in the ocean before adapting to land, fossil reveals
Spiders and their arachnid relatives may have actually originated in the sea, according to analysis of an "exquisitely preserved" fossil that lived 500 million years ago. The findings were published Tuesday in the journal Current Biology.
MORE: 99-million-year-old 'zombie' fungi found preserved in amber, scientists say
Researchers at the University of Arizona completed a detailed analysis of the brain and central nervous system of an extinct animal called Mollisonia symmetrica, according to the study. The species was previously thought to represent an ancestral member of a specific group of arthropods called chelicerates that lived during the Cambrian period -- between 540 and 485 million years ago. Chelicerates were believed to be ancestors to modern-day horseshoe crabs.
However, the scientists were surprised to discover that the neural arrangements in Mollisonia's fossilized brain are not organized like those in horseshoe crabs. Instead, they are organized the same way as in modern spiders and their relatives, the researchers said.
The anterior part of Mollisonia's body -- the prosoma -- contains a radiating pattern of segmental ganglia that control the movements of five pairs of segmental appendages, the researchers said. In addition, an unsegmented brain extends short nerves to a pair of pincer-like "claws," similar to the fangs of spiders and other arachnids.
The decisive feature that demonstrates the fossil was likely an early arachnid is the unique organization of the brain -- a reverse of the front-to-back arrangement found in present-day crustaceans, insects, centipedes and horseshoe crabs, the researchers said.
MORE: Fossils from giant possum-like mammal that lived 60 million years ago found in Texas
It's as if the brain has been "flipped backwards," which is what is seen in modern spiders," said Nick Strausfeld, a regents professor at the University of Arizona and lead author of the paper, in a statement.
This may be a crucial evolutionary development, as studies of existing spider brains suggest that a back-to-front arrangement in the brain provides shortcuts from neuronal control centers to underlying circuits, which control the spider's movements, said Frank Hirth, a reader of evolutionary neuroscience at King's College London and co-author of the paper.
The arrangement likely helps the spiders hunt stealthily and dexterity for the spinning of webs.
The arachnid brain is "unlike any other brain" on Earth, Strausfeld said.
"This is a major step in evolution, which appears to be exclusive to arachnids," Hirth said.
MORE: Fossils found in North America reveal new species of 'very odd' sea monster: Scientists
Spiders and scorpions have existed for about 400 million years with little change -- dominating the Earth as the most successful group of arthropodan predators.
The finding challenges the widely held belief that diversification occurred only after a common ancestor had moved to the shore, according to the study. Previous fossil records appeared to indicate that arachnids lived and diversified exclusively on land.
"It is still vigorously debated where and when arachnids first appeared, and what kind of chelicerates were their ancestors, and whether these were marine or semi-aquatic like horseshoe crabs," Strausfeld said.
While the Mollisonia outwardly resembles some other early chelicerates from the time period, its body was composed of two parts: a rounded "carapace" in the front and a sturdy segmented trunk ending in a tail-like structure, the analysis found. Some researchers had previously compared its body composition to that of scorpions, but no one had previously claimed that it was anything "more exotic" than a chelicerate.
The first creatures to come onto land were likely millipede-like anthropods and other ancestral, insect-like creatures -- an evolutionary branch of crustaceans, Strausfeld said.
MORE: What paleontologists learned from fossils of a 3-eyed predator that lived 500 million years ago
Early insects and millipedes were likely part of the Mollisonia-like arachnid's daily diet when they adapted to land, he added.
The first arachnids on land may have also contributed to the evolution of insect wings, a "critical defense mechanism," Strausfeld said.
The Mollisonia's lineage likely gave rise to spiders, scorpions, sun spiders, vinegarroons and whip scorpions, the researchers said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
11 minutes ago
- Medscape
Claims Data Fail to Accurately Identify MI Types
TOPLINE: Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition accurately reflecting the true diagnosis, researchers found. Nearly half of patients coded for T1MI had T2MI, whereas 26% of T2MI codes represented myocardial injury. METHODOLOGY: Researchers identified 350 randomly sampled patients with T1MI codes and 350 patients with T2MI codes during inpatient encounters using the International Statistical Classification of Diseases and Related Health Problems-10th Revision. The analysis included patients aged 65 years and older from October 1, 2017, to May 9, 2024, within eight hospitals in the Mass General Brigham system. Using the 4th Universal Definition of MI, the researchers reviewed the clinical encounters to assess evidence of plaque erosion or thrombus vs oxygen demand-supply imbalance. A second physician review was conducted for 146 challenging and 146 nonchallenging cases. TAKEAWAY: Among the 350 patients coded as having had T1MI, clinical adjudication revealed 138 (39%) as correctly diagnosed; 159 (45%) in fact had T2MI, and 35 (10%) had myocardial injury. Of the 350 patients coded as having had T2MI, 251 (72%) were confirmed, four (1%) were found to have T1MI, and 91 (26%) had myocardial injury. A second physician review demonstrated a high degree of agreement with the initial review, with a 94% agreement in nonchallenging cases and 86% in challenging cases. Hospitals equipped with vs without cardiac catheterization laboratories showed significantly lower misclassification rates (43% vs 58%; P = .0298). IN PRACTICE: 'Among individuals assigned a T1MI claims code, nearly one half have T2MI and many others have myocardial injury; fewer than one half have true T1MI,' the researchers reported. 'Our results also confirm and extend previous work showing that among those with T2MI codes, slightly more than one half have true T2MI, with most of the misclassification related to myocardial injury rather than T1MI. This has critically important implications for epidemiology and public policy' related to acute myocardial infarction. SOURCE: The study was led by Andrea Martinez, MD, of the Department of Medicine at Massachusetts General Hospital, Boston. It was published online on July 21 in Journal of the American College of Cardiology. LIMITATIONS: The results may not be generalized to other hospital systems and countries, where patterns of misclassification might differ. The researchers noted external validity assessment across multiple healthcare systems and in countries that have already introduced International Classification of Diseases-11th revision coding would be beneficial. While patterns of misclassification might have changed over time, the analysis was intentionally restricted to the period when codes for both T1MI and T2MI were available. DISCLOSURES: The study received support through a grant to Jason Wasfy from the Massachusetts General Hospital Executive Committee on Research. Individual authors reported receiving other grants and support, including grants from industry. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
41 minutes ago
- Medscape
5-Grass SLIT Shows Benefit in Allergic Rhinoconjunctivitis
TOPLINE: Five-grass-pollen liquid sublingual immunotherapy (SLIT) reduced symptoms and the need for medications to treat symptoms in patients with allergic rhinoconjunctivitis (ARC) with or without asthma — while maintaining a favorable safety profile and providing consistent benefits across ages, comorbidities, and treatment durations. METHODOLOGY: Researchers conducted a systematic review and meta-analysis to evaluate the efficacy of five-grass-pollen liquid SLIT in patients with ARC with or without asthma. Nine studies comparing the efficacy of interventional immunotherapy with that of placebo in this population were included. The key outcomes comprised symptom severity, assessed as the symptom score; a reduction in medication use, assessed as the medication score; and the incidence of adverse events (AEs). TAKEAWAY: A pooled analysis of eight studies showed a significant reduction in symptom score in the interventional immunotherapy group vs the placebo group (standardized mean difference [SMD], -0.34; 95% CI, -0.62 to -0.06; P < .05) over a mean follow-up of 19 months. Analysis of data pooled from six studies showed a significant reduction in use of drugs for symptoms in the interventional immunotherapy group vs the placebo group (SMD, -0.54; 95% CI, -0.97 to -0.10; P < .05) over a mean follow-up of 20 months. AEs occurred in 20.6% of participants in the interventional immunotherapy group vs 17.5% in the placebo group (P = .46), with treatment discontinuation rates due to AEs of 3.0% and 1.8%, respectively (P = .41). Treatment efficacy remained consistent regardless of cumulative dose, treatment duration, or asthma status. IN PRACTICE: '[The findings] suggest that the dose of five-grass SLIT-liquid can be safely adjusted for better adverse event management without compromising treatment outcomes,' the authors of the study wrote. 'This flexibility makes it possible to tailor treatment according to the patient's condition while addressing their needs and expectations,' they added. SOURCE: Danilo Di Bona, with the University of Foggia, Foggia, Italy, was the corresponding author of the study, which was published online on July 17 in the Journal of Investigational Allergology and Clinical Immunology. LIMITATIONS: The analysis had a relatively small sample size, variation in dosages and treatment durations across studies, and incomplete reporting of AEs in some studies. DISCLOSURES: This study was funded by Stallergenes Greer, a pharmaceutical company. One author declared receiving fees from this company. Some authors reported receiving consulting fees; payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events; or support for attending meetings or travel and serving on data safety monitoring boards or advisory boards for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
an hour ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.